Colorectal Cancer (CRC) Recruiting Phase 1 Trials for Nivolumab (DB09035)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04895709	A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors	Treatment	Docetaxel (DB01248) Imzokitug (DB21812) Nivolumab (DB09035) Pumitamig (DB21776)
NCT06362369	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy	Treatment	Alintegimod (DB18879) Ipilimumab (DB06186) Nivolumab (DB09035)
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Treatment	Aflibercept (DB08885) Bevacizumab (DB00112) Carboplatin (DB00958) Fluorouracil (DB00544) Ipilimumab (DB06186) Irinotecan (DB00762) Leucovorin (DB00650) NEO-212 (DB17100) Nivolumab (DB09035) Paclitaxel (DB01229) Pembrolizumab (DB09037) Regorafenib (DB08896)
NCT05919264	FOG-001 in Locally Advanced or Metastatic Solid Tumors	Treatment	Bevacizumab (DB00112) FOG-001 (DB22145) Fluorouracil (DB00544) Leucovorin (DB00650) Nivolumab (DB09035) Oxaliplatin (DB00526) Tipiracil (DB09343) Trifluridine (DB00432)
NCT05176483	Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors	Treatment	Caffeine (DB00201) Docetaxel (DB01248) Ipilimumab (DB06186) Midazolam (DB00683) Nivolumab (DB09035) Omeprazole (DB00338) Prednisone (DB00635) Relatlimab (DB14851) Warfarin (DB00682) Zanzalintinib (DB17525)
NCT07376707	A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors	Treatment	Nivolumab (DB09035) TGI-5 (DB32176)